11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.7, Iss.6, 2003-12, pp. : 771-783

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

By Fotsch Christopher Askew Ben C Chen Jian Jeffrey

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 3, 2005-03 ,pp. : 289-303

Informa Healthcare

Access to resources Recommend Favorite

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome – 11β-hydroxysteroid dehydrogenase type 1

By Stewart Paul M

Clinical Medicine, Vol. 5, Iss. 2, 2005-03 ,pp. : 142-146

Royal College Of Physicians

Access to resources Recommend Favorite

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

By Webster Scott Peter Pallin Thomas David

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 12, 2007-12 ,pp. : 1407-1422

Informa Healthcare

Access to resources Recommend Favorite

11&bgr;-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development

Current Medicinal Chemistry, Vol. 17, Iss. 5, 2010-02 ,pp. : 412-422

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of 17&bgr;-Hydroxysteroid Dehydrogenase Type 1

Current Medicinal Chemistry, Vol. 15, Iss. 2, 2008-01 ,pp. : 137-150

Bentham Science Publishers

Access to resources Recommend Favorite